Innovent Biologics, Inc.
IVBXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $51,802 | $54,461 | $44,040 | $56,702 |
| - Cash | $7,508 | $10,052 | $1,016 | $1,359 |
| + Debt | $2,831 | $3,621 | $3,229 | $2,497 |
| Enterprise Value | $47,125 | $48,029 | $46,252 | $57,840 |
| Revenue | $9,422 | $6,206 | $4,556 | $4,270 |
| % Growth | 51.8% | 36.2% | 6.7% | – |
| Gross Profit | $7,912 | $4,399 | $3,625 | $3,697 |
| % Margin | 84% | 70.9% | 79.6% | 86.6% |
| EBITDA | -$480 | -$661 | -$1,749 | -$2,375 |
| % Margin | -5.1% | -10.6% | -38.4% | -55.6% |
| Net Income | -$95 | -$1,028 | -$2,179 | -$2,729 |
| % Margin | -1% | -16.6% | -47.8% | -63.9% |
| EPS Diluted | -0.056 | -0.66 | -1.46 | -1.88 |
| % Growth | 91.5% | 54.8% | 22.3% | – |
| Operating Cash Flow | $1,287 | $148 | -$1,919 | -$2,025 |
| Capital Expenditures | -$1,705 | -$1,383 | -$1,382 | -$1,848 |
| Free Cash Flow | -$418 | -$1,236 | -$3,301 | -$3,872 |